Statements involve risks and uncertainties, and that actual results may differ materially. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to: failure to achieve sales goals due to competition or market acceptance of our products; successful introduction of generic competitors to any of our strategic brands; unexpected negative results from research and development or clinical trials of current product candidates; failure to obtain new product and therapeutic-indication regulatory approvals; failure to realize announced integration synergies due to labor, political or other issues; unfavorable exchange rate movements, particularly between the U.S. dollar and the euro; failure of holders of our exchangeable debt to exercise their exchange rights for shares of Rhodia or Clariant; delay in, or failure to achieve expected levels of net proceeds from, sales of assets; introduction of new or revised regulations or requirements pertaining to product approval, product safety, environmental protection or manufacturing processes; patent protection that proves ineffective; unexpected litigation costs or liabilities; and other risks and uncertainties that are difficult to predict. Jain N, Kulkarni S. Antinociceptive and anti-inflammatory effects of Tanacetum parthenium L. extract in mice and rats. J Ethnopharmacol 1999; 68 13 ; : 2519. Johnson E, Kadam N, Hylands D, Hylands J. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1985; 291 6495 ; : 56973. Keery R, Lumley P. Does feverfew extract exhibit phospholipase A2 inhibitory activity in vivo? Proc Brit Pharm Soc 1986; Sept; 1018. Leung A, Foster S. Feverfew. In: Encyclopedia of Common Natural Ingredients. New York: John Wiley and Sons, Inc.; 1996; 2467. Lesche W, Mazurov A, Heptinstall S, et al. An extract of feverfew inhibits interactions of human platelets with collagen substrates. Thromb Res 1987; 48 5 ; : 51118. Marles R, Kaminski J, Arnason J, et al. A bioassay for inhibition of serotonin release from bovine platelets. J Nat Prod 1992; 55 8 ; : 10441056. McGuffin M, Hobbs C, Upton R, Goldberg A eds. ; . American Herbal Products Association's Botanical Safety Handbook. Boca Raton: CRC Press; 1997. Medical Products Agency MPA ; . Naturlkemedel: Authorised Natural Remedies as of January 24, 2001 ; . Uppsala, Sweden: Medical Products Agency; 2001. MPA. See: Medical Products Agency. Murch S, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants [letter]. Lancet 1997; 350 9091 ; : 15989. Murphy J, Heptinstall S, Mitchell J. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2 8604 ; : 18992. Newall C, Anderson L, Phillipson J. Feverfew. Herbal Medicines. A Guide for Healthcare Professionals. London: The Pharmaceutical Press; 1996; 11921. O'Neill L, Barrett M, Lewis G. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: A cytotoxic effect. Br J Clin Pharmacol 1987; 23 ; : 813. Palevitch D, Earon G, Carasso R. Feverfew Tanacetum parthenium ; as a prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother Res 1997; 11: 50811. Pattrick M, Heptinstall S, Doherty M. Feverfew in rheumatoid arthritis: a double blind, placebo controlled study. Ann Rheum Dis 1989; 48 7 ; : 5479. Ph r. See: European Pharmacopoeia. Pittler M, Vogler B, Ernst E. Feverfew for preventing migraine Cochrane review ; . Cochrane Database Syst Rev 2000; 3 ; : CD002286 Pizzorno JE, Murray MT, editors. Textbook of Natural Medicine. Vol. 1, 2nd ed. New York: Churchill Livingston; 1999: 9757. Pugh W, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 1988; 40 10 ; : 7435. Reynolds J ed. ; . MartindaleThe Extra Pharmacopoeia, Thirtieth Edition. London: The Pharmaceutical Press; 1993; 70. Sumner H, Salan U, Knight D, Hoult J. Inhibition of 5-lipoxygenase and cyclooxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992; 43 11 ; : 231320. United States Pharmacopeia USP 25th Revision ; National Formulary NF 20th Edition ; . Rockville, MD: The United States Pharmacopeial Convention, Inc. 2002. USP. See: United States Pharmacopeia. Voyno-Yasenetskaya T, Loesche W, Groenewegen W, et al. Effects of an extract of feverfew on endothelial cell integrity and on cAMP in rabbit perfused aorta. J Pharm Pharmacol 1988; 40 7 ; : 5012. Williams C, Hoult J, Harborne J, et al. A biologically active lipophilic flavonol from Tanacetum parthenium. Phytochemistry 1995; 38 1 ; : 26770. Williamson L, Harvey D, Sheppard K, Fletcher J. Effect of feverfew on phagocytosis and killing of Candida guilliermondii by neutrophils. Inflammation 1988; 12 1 ; : 116.

How does feverfew work In seeking to enhance HETA's trypanocidal activity, we synthesized new analogs which were assayed for susceptibility to cleavage by Tryp-MTA-Pase and for in vitro trypanocidal activity in the T. b. brucei LAB 110 EATRO strain and at least one drug resistant KETRI clinical isolate. 8. Historically, feverfew is known to have been used in the treatment of fevers, from whence it derives its name, and also in rheumatic conditions. References 1. Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, Eglen RM: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol. 1997; 120: 1409-18. Gillberg PG, Sundquist S, Nilvebrant L: Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998; 349: 285-92. Scarpero HM, Dmochowski RR: Muscarinic receptors: what we know. Curr Urol Rep. 2003; 4: 421-8.

Feverfew breastfeeding A number of studies done in the last 10 years indicate that several commercial feverfew products contained none of the active compound parthenolide in addition, parthenolide levels of the dried herb were found to fall during storage and filgrastim. LONIDINE is a selective, partial a 2 adrenergic receptor agonist, which has both central and peripheral effects. This drug is primarily used as an antihypertensive agent, but also has sedative and analgesic properties.1"3 Recently, it has been shown that the intravenous administration of clonidine is effective in the treatment of postoperative shivering.4 Although the authors suggested that the inhibition of shivering resulted from resetting of the central threshold for shivering, the possibility of other mechanisms, such as generalized muscle flaccidity, could not be ruled out. In a subsequent study, central cooling was conducted on humans with and without clonidine 75 ug iv ; and it was concluded that core temperature Tco ; thresholds for vasoconstriction and shivering were decreased by 0.5 and 0.6C respectively.5 Further investigation of the effects of clonidine on thermoregulatory thresholds would allow comparison of its effects with those of anaesthetics and other sedatives which lower thresholds for cold responses and either raise or lower thresholds for sweating.6"12 We intended to extend the findings of previous work by determining the effect of clonidine on cold response thresholds in a protocol where shivering and peripheral blood flow were quantified. As well, skin temperature was initially increased until sweating was also initiated. Accordingly, we identified the dose response effects of clonidine on both cold and warm thermoregulatory response thresholds in a protocol where all responses were quantified and skin temperature was measured and controlled. On four occasions subjects were given either oral placebo, or clonidine 3, 6 or 9 ug-kg"1. They were immersed in a thermoneutral water bath, which was gradually warmed until sweating was established, and then gradually cooled until vasoconstriction and shivering occurred. We hypothesized that clonidine would produce a dose-dependent increase in the core temperature threshold for sweating and dosedependent decreases in core temperature thresholds for vasoconstriction and shivering i.e., cooling to a lower core temperature would be required to stimulate the latter two responses. Suggested use for feverfew leaf as a dietary supplement take 2 capsules 3 times daily with a large glass of water and flax.

Description : feverfew is a plant that is native to durope. Penstemon Digitalis "Husker's Red"-white, red foliage, h-3', sun Penstemon mexicali-rich pink, h-1', sun Penstemon Montanus-lavender, blue foliage, h-10", sun Penstemon Nitidus-blue, h-6", sun DT Penstemon Pinifolius -red-orange- ?, h-8".sun Penstemon Speciosus-blue, h-2', sun Pnstemon Strictus-blue, h-1', sun , DT Penstemon Tenuis-lavender-blue, h-2', sun, DT Penstemon Whippleanus-dark purple, h-1', sun perennial Persicaria Filliformis-, green with red foliage, h-1', sun- part shade perennial Persicaria"Painters Pallete"-green, white and red foliage, h-1, 5', sun perennial Persicaria Polymorpha-green with white foliage, h-5-6', part shade, invasive in sun perennial Persicaria"Red Dragon"-dark red ornamental foliage, h-4', sun perennial Petrorhagia Saxifrage-Light pink, h-12", sun poor soil, DT perennial Phlox 'Bill Baker'- pink, h-20", sun perennial Phlox Subulata "Candy Stripes"-white with pink, h-4-6", sun , DT perennial Phlox Subulata-Moss phlox-hot pink-h-6", sun DT perennial Phlox subulata-Moss phlox"Emerald Cushion Blue"-lavender blue, h-6", sun, DT perennial Phlox Subulata-Moss phlox"Fort Hill"-pink, h-6", sun DT perennial Phlox Subulata-Moss Phlox"Snoflake"white -h-4", sun , DT perennial Phlox paniculata -lavender-old variety from friend's garden .Name? I named it Heather in her memory.H-5', sun perennial Phlox paniculata - white, h-5', sun perennial Phlox paniculata"Bright Eyes"- pink with crimson, h-36", sun perennial Phlox paniculata"Norah Leigh"-pink with variegate foliage, h-28", sun perennial Phlox paniculata "Orange perfection"-salmon-orange, h-28", sun perennial Phlox Stolonifera"Home Fires"-pink, h-10", partial to full shade perennial Phlox Stolonifera"Sherwood Purple" -purple-blue, h-10", part to full shade perennial Phalaris arundinacea-Ribbon Grass-green with white foliage, h-3', sun-part shade, invasive grass Physocarpus "Darts Gold"Ninebark-gold foliage, h-6', sun , DT shrub Physocarpus red foliage , pink fl, h-6', sun , DT shrub Physostegia Virgiiana 'variegata'-pink, greenand creamy white foliage with pink tint in 08, h-45', sun-part shade perennial Phyteuma Sieberi-blue with hint of purple, h-8", sun perennial Platycodon Grandiflorus-Balloon flower-shade of purpe blue , h30", sun-part shade perennial Platycodon Grandiflorus"Hakone White"-double white, h-3', sun perennial Podophyllum Peltatum - Mayapple-white, ornamental foliage, native, h-1-1, 5', part shade perennial Polygonatum Canaliculatum-Great Solomon's Seal- white, h-4-5', part shade perennial Polygonum Affine-Knotweed-pink, h-up to 1', sun , ground cover perennial Potentilla Megalantha -yellow, h-6-13", part shade perennial Primula Floridae"Giant Cowslip"-yellow'h-2', part shade perennial Primula Frondosa-lavender, mealy grey-green foliage, h-3", part shade, moist perennial Primula Japonica-Candelabra primrose-mix of colors, h-2', sun to part shade, moist perennial Primula Oxslip-yellow, h-20", part shade, moist perennial Primula Pubescens-mix of color, interesting foliage, h-6", part shade perennial Primula Rosea-rose with yellow, h-3", part shade , moist to wet perennial and flecainide!

Feverfew tea

Feverfew uses

How does feverfew work, feverfew breastfeeding, feverfew rash, feverfew tea and feverfew uses. Feverfew herbal supplement, feverfew information, side effects of feverfew and feverfew leaf or feverfew treatment.